Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Recruiting
Observational Study
Type 2 Diabetes Mellitus in Remission
Metabolic Associated Fatty Liver Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,900 (estimated)
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The glob…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
* UAP were measured based on iLivTouch
* Willing to attend this study and able to provide the written informed consent.
Exclusion Criteria:
* Other types of diabetes
* P…
Contacts